Cellogicus™ Cell Delivery Platform
Cellular Logistics has developed a novel cell delivery platform. When combined with a therapeutic cell line, Cellogicus™ dramatically improves post-injection cell retention. Most stem cell treatments fail because the implanted cells die (anoikis) or are transported out of the target area by natural body functions. Cellogicus™ is easily co-incubated with a variety of progenitor cell type, including allogeneic bone marrow derived mesenchymal stem cells, allogeneic induced pluripotent stem cells, allogeneic epicardial progenitor cells, allogeneic embryonically derived arteriolar progenitor cells and allogeneic macrophages. Small animal testing has demonstrated significantly improved localized cell retention and survival rates. The Company is actively seeking collaborative partnership to develop combination regenerative medicine therapeutics.
Cellogicus™ is a powdered extracellular matrix (A) that is reconstituted with an injectable solution containing a dose of therapeutic cells (B). Adherent therapeutic cells rapidly attach to Cellogicus™ (C) creating a platform that lodges within the wall of the heart from which the therapeutic cells can exert their targeted effects. The therapeutic cell population can now be delivered to the damaged heart via cardiac catheter or needle and syringe.